ALNYLAM PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$7.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$7.24M, a 195.76% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$4.80M.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $1.68M.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $8.18M, a 16.65% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $14.42M.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$11.14M, a 152.37% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $21.28M.
- ALNYLAM PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$11.39M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.24M 10-Q · filed 2026-07-30 | -$12.04M 10-Q · filed 2026-07-30 | -$10.36M derived: sum of 3 quarters · filed 2026-07-30 | -$2.19M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$4.80M 10-Q · filed 2026-07-30 | -$3.12M derived: sum of 2 quarters · filed 2026-07-30 | $5.06M derived: sum of 3 quarters · filed 2026-07-30 | $12.62M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $9.86M derived: sum of 2 quarters · filed 2026-02-12 | $17.42M derived: sum of 3 quarters · filed 2026-07-30 | $14.42M 10-K · filed 2026-02-12 |
| 2025-09-30 | $8.18M 10-Q · filed 2025-10-30 | $15.74M derived: sum of 2 quarters · filed 2026-07-30 | $12.74M 10-Q · filed 2025-10-30 | $3.05M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $7.57M 10-Q · filed 2026-07-30 | $4.57M 10-Q · filed 2026-07-30 | -$5.13M derived: sum of 3 quarters · filed 2026-07-30 | $4.68M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$3.00M 10-Q · filed 2026-07-30 | -$12.69M derived: sum of 2 quarters · filed 2026-07-30 | -$2.88M derived: sum of 3 quarters · filed 2026-07-30 | -$10.53M derived: sum of 4 quarters · filed 2026-07-30 |
| 2024-12-31 | -$9.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $119.00K derived: sum of 2 quarters · filed 2026-02-12 | -$7.53M derived: sum of 3 quarters · filed 2026-02-12 | -$11.14M 10-K · filed 2026-02-12 |
| 2024-09-30 | $9.81M 10-Q · filed 2025-10-30 | $2.16M derived: sum of 2 quarters · filed 2025-10-30 | -$1.45M 10-Q · filed 2025-10-30 | $7.51M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$7.65M 10-Q · filed 2025-10-30 | -$11.26M 10-Q · filed 2025-07-31 | -$2.30M derived: sum of 3 quarters · filed 2026-02-12 | $2.44M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$3.61M 10-Q · filed 2025-10-30 | $5.35M derived: sum of 2 quarters · filed 2026-02-12 | $10.09M derived: sum of 3 quarters · filed 2026-02-12 | $12.14M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $8.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $13.71M derived: sum of 2 quarters · filed 2026-02-12 | $15.75M derived: sum of 3 quarters · filed 2026-02-12 | $21.28M 10-K · filed 2026-02-12 |
| 2023-09-30 | $4.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $6.79M derived: sum of 2 quarters · filed 2024-10-31 | $12.31M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $7.57M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $5.53M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | -$11.39M 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |